The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 14 of the 40 sources its claims cite were checked for support.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessAbstract
BACKGROUND: Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group). The primary end point was progression-free survival. RESULTS: white cells), as compared with 4.6% of those in the control group (P<0.001); results below the threshold for minimal residual disease were associated with improved outcomes. The most common adverse events of grade 3 or 4 during treatment were neutropenia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the control group), thrombocytopenia (in 12.7% vs. 13.5%), and anemia (in 12.4% vs. 19.6%). Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2. CONCLUSIONS: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX ClinicalTrials.gov number, NCT02076009 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 of 40 cited sources checked · 9 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, this category of minimal residual disease status has not been examined to date in patients with relapsed or refractory multiple myeloma, in part because of limited availability of data showing a correlation between depth of response and survival outcomes in patients at this stage of the disease.7”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The “Relapsed and/or refractory” section (page unavailable) says data linking depth of response to outcomes are limited, supporting the citing sentence’s rationale. The “Redefining CR” section discusses minimal residual disease (MRD) studies in newly diagnosed patients, but does not state that MRD status had never been examined in relapsed or refractory patients. The relapsed-setting section’s “MR” means minimal response, not minimal residual disease. (LLM, conf=0.78)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As in our trial (POLLUX), the addition of daratumumab to a standard-of-care regimen of bortezomib and dexamethasone in the CASTOR trial was associated with a significantly lower risk of disease progression or death.18”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
What the sources say
- Supportedcites [18] source
The Trial Treatments section (p. 3) confirms that CASTOR compared daratumumab plus bortezomib and dexamethasone with bortezomib and dexamethasone alone. The Discussion (p. 11) reports significantly longer progression-free survival and a 61.4% lower risk of disease progression or death in the daratumumab group. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
What the sources say
- Not checked — no full text of the sourcecites [27] source
- Supportedcites [28] source
The Safety section identifies thrombocytopenia, gastrointestinal events, and rash as adverse events observed with lenalidomide-dexamethasone, and describes management of gastrointestinal events with supportive therapy and dose adjustment. This supports the part of the sentence attributed to this paper: the known toxic effects of lenalidomide-dexamethasone. The daratumumab-specific part has separate citations and is not attributed to this source. (LLM, conf=0.90)
- Supportedcites [30] source
This citation is attached to the known toxic effects of lenalidomide and dexamethasone, not to the daratumumab-specific part of the sentence. The Randomization and Study Treatment section identifies a lenalidomide–dexamethasone control group, and the Safety section and Table 3 report its adverse events. The paper does not assess the daratumumab combination. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [31] source
- Not checked — no full text of the sourcecites [9] source
- Supportedcites [10] source
This source is cited for the known toxic effects of daratumumab, not for the safety of the three-drug combination. The Safety section (p. 5) reports that most adverse events with daratumumab were grade 1 or 2, and the Discussion (p. 11) describes an acceptable safety profile and mostly mild infusion-related reactions. (LLM, conf=0.89)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were observed in the intentionto-treat population (Table S3 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consistent with the higher rates of deeper responses in the daratumumab group, the rate of results below the threshold for minimal residual disease was significantly higher in the daratumumab group than in the control group (by 3 to 5 times) at all evaluated thresholds (1 tumor cell per 10 4 , 10 5 , and 10 6 white cells) (Fig. S4 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the interim analysis, a total of 75 deaths had been observed (30 patients in the daratumumab group and 45 in the control group) (Table S4 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A significantly higher rate of overall response was observed in the daratumumab group than in the control group (92.9% vs. 76.4%,P<0.001), as was a higher rate of complete response or better (43.1% vs. 19.2%,P<0.001).”
- Also stated in: § Efficacy · plain
“the rate of complete response or better (43.1% vs. 19.2%,P<0.001).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Efficacy · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Progression-free survival was similarly prolonged in the daratumumab group among patients who had previous exposure to lenalidomide and those who had no previous exposure, as compared with the control group (Fig. S3 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median progression-free survival was not reached (95% CI, could not be estimated) in the daratumumab group, as compared with 18.4 months (95% CI, 13.9 to could not be estimated) in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with a partial response or better, the rate of progression-free survival at 12 months was 87.8% (95% CI, 83.1 to 91.3) in the daratumumab group versus 73.6% (95% CI, 67.0 to 79.1) in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Supportedcites [8] source
The Ab generation section states that all antibodies described, including daratumumab, were human IgG1, κ antibodies. The Discussion identifies daratumumab as a human IgG1 antibody that binds CD38. The later phase 1–2 efficacy claims carry separate citations and are not attributed to this source. (LLM, conf=0.94)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point was progression-free survival, with progression determined with the use of a validated computer algorithm that combined laboratory results (e.g., M-protein level) and applicable imaging and generated the outcome according to IMWG criteria (see the Supplementary Appendix).20,21 This algorithm previously showed very strong concordance with independent reviews in a phase 2 study”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > End Points and Assessments
What the sources say
- Not checked — no full text of the sourcecites [20] source
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [9] source
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“A phase 3 trial of bortezomib and dexamethasone, with or without daratumumab, met its primary end point at the interim analysis and showed a significantly higher rate of progression-free survival, with a 61% lower risk of progression or death in the daratumumab group than in the control group.18”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Supportedcites [18] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“After the implementation of guidelines from other studies of daratumumab regarding the management of infusion-related reactions, infusion-related reactions were consistent with daratumumab monotherapy 9,10 and combination therapy, 18,19,32 were mostly of grade 1 or 2, and usually occurred during the first infusion.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
What the sources say
- Not checked — no full text of the sourcecites [9] source
- Supportedcites [10] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [18] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Could not verifycites [32] Chari A, 2015, Blood sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Response was assessed according to the Uniform Criteria Consensus recommendations of the International Myeloma Working Group.20,21”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
What the sources say
- Not checked — no full text of the sourcecites [20] source
- Supportedcites [21] source
The Response criteria section recommends using the IMWG uniform response criteria in clinical trials and says the panel endorsed their response definitions. The citation therefore supports the identification of the criteria used; it does not independently document how the citing study assessed response. (LLM, conf=0.93)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Daratumumab interferes with laboratory-based bloodcompatibility tests, including indirect Coombs' test, because of binding to CD38 on red cells.26”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
What the sources say
- Supportedcites [26] source
The Discussion says daratumumab interferes with blood compatibility testing because it binds directly to CD38 on red cells. The “DARA causes plasma panreactivity in vitro” section reports panreactivity at the antihuman globulin phase, supporting the reference to the indirect Coombs test. (LLM, conf=0.93)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, in the time-toevent analysis of disease progression, a total of 148 events (in 44 patients [15.4%] in the daratumumab group vs. 104 [36.7%] in the control group) were observed (hazard ratio, 0.34; 95% CI, 0.23 to 0.48; P<0.001).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients with adverse events leading to the discontinuation of treatment was similar in the two groups: 6.7% in the daratumumab group and 7.8% in the control group.”
- Also stated in: § Patients who have very good partial responses · plain
“The rates of treatment discontinuation owing to adverse events were low and similar in the two groups.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Patients who have very good partial responses · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment effect of daratumumab was consistent regardless of previous exposure to lenalidomide (a limitation being the relatively small number of patients with previous exposure to lenalidomide) and across all subgroups, including patients 65 years of age or older, those with disease that was refractory to proteasome inhibitors or the most recent line of therapy, those with International Stag”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although higher rates of neutropenia and infusion-related reactions (primarily during the first infusion) were observed with this combination than with lenalidomide and dexamethasone alone, these events did not result in higher rates of treatment discontinuation or death.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After continued treatment, responses deepened, with a rate of complete response or better that was twice as high with daratumumab as with the backbone regimen alone.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These reactions were mostly of grade 1 or 2; a total of 15 patients (5.3%) had grade 3 infusion reactions, and no patient had an event of grade 4 or 5.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedn = 15Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall response No. with response 261 211 -Rate -% (95% CI) 92.9 (89.2-95.6)76.4 (71.0-81.3)<0.001”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Serious adverse events were reported in 48.8% of the patients in the daratumumab group and in 42.0% of those in the control group, among which pneumonia was the most common (in 8.1% of the patients in the daratumumab group and in 8.5% of those in the control group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rate of infection of grade 3 or 4 was also slightly higher in the daratumumab group than in the control group (28.3% and 22.8%, respectively); the most common infection of grade 3 or 4 was pneumonia, which occurred at similar rates in the two groups.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events leading to death were acute kidney injury (in 0.4% of the patients in the daratumumab group and in 1.1% in the control group), septic shock (in 1.1% and 0.4%, respectively), and pneumonia (in 0.7% in each group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedn = 11Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“incidences of grade 3 or 4 diarrhea, fatigue, nausea, and dyspnea were slightly higher in the daratumumab group than in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Stringent complete response § 51 (18.1) 20 (7.2) -”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of daratumumab infusionrelated reactions of any grade was 47.7%, with 92% of the reactions occurring during the first infusion.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events (in ≥1% of the patients in either group) that led to the discontinuation of treatment included pneumonia (in 1.1% of the patients in the daratumumab group and in 0.7% of those in the control group), pulmonary embolism (in 1.1% in the control group), and deterioration in general physical health (in 1.1% in the daratumumab group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite higher rates of neutropenia in the daratumumab group, the rate of infection of grade 3 or 4 was only slightly higher in the daratumumab group than in the control group (28% vs. 23%).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As in the CASTOR trial, 18 the addition of daratumumab to the backbone regimen in our trial resulted in a significantly higher rate of overall response, deeper responses, and longer duration of response.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common infusion-related reactions were cough (in 8.5% of the patients), dyspnea (in 8.5%), and vomiting (in 5.7%) (Table S5 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“A phase 1-2 study of daratumumab, lena-lidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma showed that this combination provided therapeutic benefits, no dose-limiting toxic effects, and an 81% rate of overall response, including a 25% rate of stringent complete response”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The group-sequential design had one planned interim analysis to evaluate the primary end point.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“he incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved outcomes in patients with multiple myeloma over the past 10 years, [1][2][3]”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [1][2][3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was approved by the independent ethics committee or institutional review board at each site before the initiation of the trial.Patients provided written informed consent, and the trial was conducted in accordance with the principles of the Declaration of Helsinki and current International Conference on Harmonisation Good Clinical Practice guidelines.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Trial Design
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An independent data and safety monitoring committee was established to periodically review unblinded safety data.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > End Points and Assessments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“At 18 months, the rate of progression-free survival was 72%, and the rate of overall survival was 90%.19”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common reasons for the discontinuation of treatment were progressive disease (in 14.1% of the patients in the daratumumab group vs. 34.2% of those in the control group) and adverse events (in 6.7% vs. 8.2%) (Fig. S2 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients and Treatment
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We calculated that approximately 560 patients with 295 events (disease progression or death) would be needed to provide the trial with 85% power to detect a 30% lower risk of disease progression or death (hazard ratio, 0.70), using a log-rank test, with an overall two-sided significance level of 0.05.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This suggests that results below the threshold for minimal residual disease also should be a treatment goal in the context of relapsed or refractory disease.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Figure 2. Prespecified Subgroup Analyses.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Shown are the results of the Kaplan-Meier analysis of progression-free survival among patients in the intention-totreat population, which included all patients who underwent randomization.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper relies on this without support.
Relapse can occur even after standard complete remission in the context of first-line therapy.
“Relapse can occur even after standard complete remission in the context of first-line therapy, and studies are therefore evaluating deeper responses in a category termed “minimal residual disease-negative””
The paper relies on this without support.
The combination of lenalidomide and dexamethasone is an appropriate standard control regimen for patients with relapsed or refractory multiple myeloma who have received one or more previous lines of therapy.
“we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group).”
The paper relies on this without support.
The open-label design does not bias the assessment of progression-free survival.
“In this randomized, open-label, multicenter, phase 3 trial, we assigned patients who had relapsed or refractory multiple myeloma and had received one or more lines of previous therapy to receive either daratumumab, lenalidomide, and dexamethasone (daratumumab group) or lenalidomide and dexamethasone (control group).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recently approved monoclonal antibody, daratumumab, which targets CD38 (a receptor highly expressed on myeloma cells), has become a favorite for later line induction regimens [35,36].”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“Response rates to single-agent lenalidomide have consistently been surpassed by those achieved with doublet or triplet combinations, which has been taken as evidence for synergistic activity of this agent with other anti-myeloma agents48.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Control-group adverse-event discontinuation rates differ
MinorThe results give 8.2% of control-group patients as discontinuing treatment because of adverse events, but the safety section gives 7.8% for adverse events leading to treatment discontinuation. The text does not explain the difference.
“The most common reasons for the discontinuation of treatment were progressive disease (in 14.1% of the patients in the daratumumab group vs. 34.2% of those in the control group) and adverse events (in 6.7% vs. 8.2%)”
“The percentage of patients with adverse events leading to the discontinuation of treatment was similar in the two groups: 6.7% in the daratumumab group and 7.8% in the control group.”
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationKumar, S. K., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2013) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,383
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Krejcik J, Blood
- Plesner T, Blood
Cited by
Sorted by citations
Items 501–600 of 1,433
Frerichs, K. A., Verkleij, C. P. M., Dimopoulos, M. A., Soto, J. A. M., Zweegman, S., Young, M. H., Newhall, K. J., Mutis, T., & van de Donk, N. W. C. J. (2021) · Cancers · doi:10.3390/cancers13102452 · Cited by 21
Self-citationVitkon, R., Netanely, D., Levi, S., Ziv‐Baran, T., Ben-Yzak, R., Katz, B., Benyamini, N., Trestman, S., Mittelman, M., Cohen, Y. C., et al. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211035272 · Cited by 22
“11 Treatment regimens were classified into four categories: (1) Dara-PIs: Dara administered in combination with dexamethasone and PIs (carfilzomib, bortezomib, or ixazomib); (2) Dara-IMiDs: Dara administered in combination with dexamethasone and IMiDs (lenalidomide, or thalidomide, or pomalidomide); (3) Dara-PIs-IMiDs…”
MethodThe multi-faceted potential of CD38 antibody targeting in multiple myeloma
Shallis, R. M., Terry, C. M., & Lim, S. H. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1990-2 · Cited by 20
New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
Richardson, P. G. G., Kumar, S. K., Laubach, J. P., Paba‐Prada, C. E., Gupta, N., Berg, D. T., de Velde, H. J. V., & Moreau, P. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s102328 · Cited by 20
“…elotuzumab and daratumumab have demonstrated encouraging PFS when administered in combination with the proteasome inhibitor bortezomib or immunomodulatory drug lenalidomide, plus dexamethasone, 30,31,43 with daratumumab approved as a single agent and showing particular promise in triplet regimens.”
Self-citationMadduri, D., Dhodapkar, M. V., Lonial, S., Jagannath, S., & Cho, H. J. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.08.002 · Cited by 20
Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date
Richter, J. R., Sanchez, L. J., & Thibaud, S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.04.004 · Cited by 20
Richardson, P. G. G., Harrison, S. J., Bringhen, S., Schjesvold, F. H., Yong, K., Campana, F., Le-Guennec, S., Macé, S., & Dimopoulos, M. A. (2021) · Future Oncology · doi:10.2217/fon-2021-0568 · Cited by 20
Self-citationRole of daratumumab in the frontline management of multiple myeloma: a narrative review
Yadav, S., Gundeti, S., Bhave, A. A., Deb, U., Dixit, J., & Mishra, K. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2246651 · Cited by 20
Malard, F., Harousseau, J., & Mohty, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.005 · Cited by 19
Mey, U., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T. N., Jehner, P., Rauh, J., Taverna, C., Schmid, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14481 · Cited by 22
Holstein, S. A., Avet‐Loiseau, H., Hahn, T., Ho, C. M., Lohr, J. G., Munshi, N. C., Paiva, B., Pasquini, M. C., Tario, J. D., Usmani, S. Z., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.774 · Cited by 20
Self-citationKatodritou, E., Kyrtsonis, M., Delimpasi, S., Kyriakou, D. S., Symeonidis, A. S., Spanoudakis, E., Vasilopoulos, G., Anagnostopoulos, Α., Kioumi, A., Zikos, P., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3361-2 · Cited by 20
“The role of the immune system may be critical in this regard, especially when considering the results of the recent triple combination of Len/Dex with immunotherapy, such as with daratumumab [19] and elotuzumab [20] which show impressive results especially when given at first relapse [21].”
BackgroundSato, S., Kambe, E., & Tamai, Y. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1726-18 · Cited by 20
“2%, respectively; lymphopenia also occurred in patients who were treated with daratumumab (5, 21).”
BackgroundHow I treat elderly patients with plasma cell dyscrasias
Gavriatopoulou, M., Fotiou, D., Ntanasis‐Stathopoulos, I., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2018) · Aging · doi:10.18632/aging.101707 · Cited by 20
“In the POLLUX trial RRMM patients were randomized to receive Rd versus Daratumumab-Rd and the PFS benefit was even more pronounced ≥ 75-yearold patients, with higher rate of AEs but comparable discontinuation rates [51].”
Self-citationCook, G., Royle, K., O’Connor, S. J. M., Cairns, D. A., Ashcroft, A. J., Williams, C. D., Hockaday, A., Cavenagh, J. D., Snowden, J. A., Ademokun, D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15782 · Cited by 19
“…of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. British Journal of Haematology, 2019, 185, 450–467 documented (Lonial et al, 2015; Stewart et al, 2015; Dimopoulos et al, 2016; Moreau et al, 2016), so defining its universality of impact becomes difficult.”
BackgroundThe pharmacologic management of multiple myeloma in older adults
Dempsey, J. L., Johns, A. C., Rosko, A. E., & Lazarus, H. M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1577822 · Cited by 20
“In the relapsed, refractory disease setting, daratumumab currently is approved to be administered as monotherapy with dexamethasone or in combination with bortezomib, lenalidomide or pomalidomide [56,103,104].”
BackgroundHolstein, S. A., Al-Kadhimi, Z. S., Costa, L. J., Hahn, T., Hari, P., Hillengaß, J., Jacob, A. P., Munshi, N. C., Oliva, S., Pasquini, M. C., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.09.015 · Cited by 19
Stocker, N., Gaugler, B., Ricard, L., de Vassoigne, F., Marjanovic, Z., Mohty, M., & Malard, F. (2020) · Cancer Medicine · doi:10.1002/cam4.2827 · Cited by 20
Evolving Role of Daratumumab: From Backbencher to Frontline Agent
Jain, A., & Ramasamy, K. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.03.010 · Cited by 20
Basset, M., Kimmich, C. R., Schreck, N., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17685 · Cited by 20
Self-citationImmunotherapy in Multiple Myeloma—Time for a Second Major Paradigm Shift
Mohan, M., Hari, P., & Dhakal, B. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00032 · Cited by 21
Mapping the cancer surface proteome in search of target antigens for immunotherapy
Meo, F. D., Kale, B. J., Koomen, J. M., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.019 · Cited by 19
Kiesewetter, B., Cherny, N. I., Boissel, N., Cerisoli, F., Dafni, U. G., de Vries, E. G. E., Ghia, P., Gökbuget, N., González‐Calle, V., Huntly, B. J. P., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000611 · Cited by 19
Qi, T., Qu, J., Tu, C., Lu, Q., Li, G., Wang, J., & Qu, Q. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.596777 · Cited by 19
Lecat, C. S. Y., Taube, J. B., Wilson, W., Carmichael, J., Parrish, C., Wallis, G., Kyriakou, C. A., Lee, L. S. H., Mahmood, S., Papanikolaou, X. D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703233 · Cited by 20
Self-citationTherapeutics to harness the immune microenvironment in multiple myeloma
Ignatz-Hoover, J. J., & Driscoll, J. J. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.23 · Cited by 21
Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
Xing, L., Liu, Y., & Liu, J. (2023) · Cancers · doi:10.3390/cancers15082240 · Cited by 19
Mollee, P. N., Reynolds, J., Janowski, W., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012539 · Cited by 19
Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma
Ailawadhi, S., DerSarkissian, M., Duh, M. S., Lafeuille, M.-H., Posner, G., Ralston, S., Zagadailov, E. A., Ba-Mancini, A., & Rifkin, R. M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.01.009 · Cited by 20
The effect of novel therapies in high-molecular-risk multiple myeloma.
Lancman, G., Tremblay, D. A., Barley, K. M., Barlogie, B., Cho, H. J., Jagannath, S., Madduri, D., Moshier, E. L., Parekh, S. S., & Chari, A. (2017) · PubMed · Cited by 19
Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma
Hoylman, E., Brown, A. B., Perissinotti, A. J., Marini, B. L., Pianko, M. J., Ye, J. C., Campagnaro, E. L., & Nachar, V. R. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1688324 · Cited by 19
“Daratumumab has a 30% ORR in patients with 3 or more prior lines of therapy, with further improvements in ORR when combined with either a proteasome inhibitor or an immunomodulatory agent [4,5,13].”
BackgroundUpdates in the Diagnosis and Management of AL Amyloidosis
Cook, J., Muchtar, E., & Warsame, R. M. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00574-5 · Cited by 19
Choline PET/CT in Multiple Myeloma
Mesguich, C., Hulin, C., Lascaux, A., et al. (2020) · Cancers · doi:10.3390/cancers12061394 · Cited by 19
“It improves the depth and duration of response in combination with other antimyeloma agents [42,43].”
BackgroundLuo, M., Usmani, S. Z., Mateos, M., Nahi, H., Chari, A., Miguel, J. F. S., Touzeau, C., Suzuki, K., Kaiser, M., Carson, R. L., et al. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1771 · Cited by 19
Self-citationArcuri, L. J., & Américo, A. D. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04404-3 · Cited by 18
The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies
Swan, D., Routledge, D. J. M., & Harrison, S. J. (2021) · British Journal of Haematology · doi:10.1111/bjh.17805 · Cited by 19
Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
Pozzi, S., Bari, A., Pecherstorfer, M., & Vallet, S. (2021) · Cancers · doi:10.3390/cancers13194978 · Cited by 20
“Daratumumab (lenalidomide, dexamethasone) [89] 4% 8.”
Kalff, A., Khong, T. T., Mithraprabhu, S., Bergin, K., Reynolds, J., Bowen, K. M., Thakurta, A., Guzman, R. Z., Wang, M., Couto, S. S., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1571201 · Cited by 19
Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab
Moore, D. C., Arnall, J. R., Thompson, D. L., Martin, A. L., Robinson, J., Ndiaye, A. P., Paul, B. A., Atrash, S., Bhutani, M., Voorhees, P. M., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.024 · Cited by 19
Self-citationMoreau, P., Hébraud, B., Facon, T. T. F., Leleu, X. P., Hulin, C., Hashim, M., Hu, Y., Caillot, D., Benboubker, L., Zweegman, S., et al. (2020) · Immunotherapy · doi:10.2217/imt-2020-0266 · Cited by 18
Self-citationBaum, N., Fliegert, R., Bauche, A., Hambach, J., Menzel, S., Haag, F., Bannas, P., & Koch‐Nolte, F. (2020) · Cancers · doi:10.3390/cancers13010076 · Cited by 18
Baertsch, M., Fougereau, M., Hielscher, T., Sauer, S., Breitkreutz, I., Jordan, K., Müller‐Tidow, C., Goldschmidt, H., Raab, M., Hillengaß, J., et al. (2021) · Cancers · doi:10.3390/cancers13184706 · Cited by 18
Self-citationPathogenesis and treatment of multiple myeloma bone disease
Hiasa, M., Harada, T., Tanaka, E. I., & Abe, M. (2021) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2021.08.006 · Cited by 18
Efficace, F., Cottone, F., Sparano, F., Caocci, G., Vignetti, M., & Chakraborty, R. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.009 · Cited by 19
Girmenia, C., Cavo, M., Corso, A., Raimondo, F. D., Musto, P., Offidani, M., Petrucci, M. T., Rosato, A., & Barosi, G. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103623 · Cited by 19
Baertsch, M., Schlenzka, J., Hielscher, T., et al. (2025) · Blood · doi:10.1182/blood.2024027342 · Cited by 18
Self-citationAdvances in immunotherapy in multiple myeloma
Boussi, L. S., & Niesvizky, R. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000407 · Cited by 18
Daratumumab: Therapeutic asset, biological trap!
Deneys, V., Thiry, C., Frelik, A., Debry, C., Martin, B., & Doyen, C. (2018) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2017.12.001 · Cited by 18
Yamamoto, T., Kosaka, N., Hattori, Y., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7030055 · Cited by 18
“Recently, use of a monoclonal antibody, daratumumab (anti-CD38 antibody), drastically improved the prognosis of MM [71].”
BackgroundUsmani, S. Z., Khan, I., Chiu, C. W., Foureau, D., Druhan, L. J., Rigby, K., Casneuf, T., & Sasser, A. K. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0096-7 · Cited by 18
“The CASTOR study of daratumumab plus bortezomib and dexamethasone in patients with a median of two lines of therapy showed an overall response rate of 82.9% versus 63.2% in the control arm [1].”
InfluentialSelf-citationDanhof, S., Strifler, S., Hose, D., Kortüm, K. M., Bittrich, M., Hefner, J., Einsele, H., Knop, S. T., & Schreder, M. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2807-1 · Cited by 18
Dimopoulos, M. A., Niesvizky, R., Weisel, K. C., Siegel, D. S. D., Hájek, R., Mateos, M., Cavo, M., Huang, M., Zahlten‐Kumeli, A., & Moreau, P. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0300-y · Cited by 19
Self-citationCNV Radar: an improved method for somatic copy number alteration characterization in oncology
Soong, D., Stratford, J. K., Avet‐Loiseau, H., et al. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-3397-x · Cited by 18
Self-citationDihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
Chen, Y., Li, R., Zhu, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00767 · Cited by 18
“treatment of MM despite the development of resistance in patients after prolonged exposure to its high doses (10), which in turn, is associated with poor prognosis of MM.”
BackgroundKaufman, J. L., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P. J., Kım, K., Takezako, N., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00375-2 · Cited by 18
Self-citationEfficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia
Parrondo, R. D., Moustafa, M. A., Reeder, C. B., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.01.002 · Cited by 18
Cottini, F., Huang, Y., Williams, N., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.575168 · Cited by 18
“A high-risk cytogenetic profile was defined by a finding of t(4;14), t(14;16), t(14;20), del(17p), or hypodiploid karyotype.”
BackgroundPlesner, T., Dimopoulos, M. A., Oriol, A., Miguel, J. F. S., Bahlis, N. J., Rabin, N. K., Suzuki, K., Yoon, S., Ben‐Yehuda, D., Cook, G., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17435 · Cited by 18
“In the phase 3 POLLUX study, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) resulted in superior progression-free survival (PFS) compared with lenalidomide and dexamethasone (Rd) alone.(11) D-Rd continued to demonstrate prolonged PFS, higher overall response rate, higher rates of complete respon…”
MethodResultInfluentialSelf-citationTouzeau, C., Quignot, N., Meng, J., Jiang, H., Khachatryan, A., Singh, M., Taieb, V., Chauny, J.-V., & Désaméricq, G. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04522-y · Cited by 18
Immunotherapy of Multiple Myeloma: Promise and Challenges
Abramson, H. N. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s306103 · Cited by 19
Bozic, B., Rutner, J., Zheng, C., Ruckser, R., Selimi, F., Racz, K., Köcher, M., Tatzreiter, G., & Sebesta, C. (2021) · Cancers · doi:10.3390/cancers13205036 · Cited by 17
“Daratumumab plus lenalidomide plus dexamethasone is the most effective combination available for a first-time myeloma relapse that is not refractory to lenalidomide [77].”
BackgroundYimer, H. A., Melear, J. M., Faber, E. A., Bensinger, W., Burke, J. M., Narang, M., Stevens, D. A., Gray, K. S., Lutska, Y., Bobba, P., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2076847 · Cited by 18
Hematologic Malignancies: Plasma Cell Disorders
Dhodapkar, M. V., Borrello, I., Cohen, A. D., & Stadtmauer, E. A. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175546 · Cited by 20
A Benefit–Risk Analysis Approach to Capture Regulatory Decision‐Making: Multiple Myeloma
Raju, G. K. P., Gurumurthi, K., Domike, R., Kazandjian, D. G., Landgren, O., Blumenthal, G. M., Farrell, A. T., Pazdur, R., & Woodcock, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.871 · Cited by 19
Daratumumab and Blood-Compatibility Testing
Bueno, J.-L., Alarcón, A., & Krsnik, I. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1613868 · Cited by 17
Hadidi, S. A., Miller-Chism, C. N., Kamble, R. T., & Mims, M. P. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.04.004 · Cited by 17
Wang, H., Liu, H., Sun, C., Liu, C., Jiang, T., Yin, Y., Xu, A., Pang, Z., Zhang, B., & Hu, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020274 · Cited by 17
“MM is still incurable despite exciting advances over the past few years by the application of different new strategies such as immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, etc. [1,2].”
Wang, Y., Li, Y., & Chai, Y. (2021) · Journal of International Medical Research · doi:10.1177/03000605211038135 · Cited by 17
Chu, T.-H., Vo, M.-C., Thangaraj, J. L., Ahn, S., Kim, M., Song, G., Yang, D., Ahn, J., Kim, H., Jung, S., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101413 · Cited by 16
Bruzzese, A., Derudas, D., Galli, M., Martino, E. A., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Farina, G., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3031 · Cited by 17
Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
Fatoki, R. A., Koehn, K., Kelkar, A. H., Hadidi, S. A., Mehra, N., Mian, H. S., Landgren, O., Kazandjian, D. G., Hoffman, J. E., Sborov, D. W., et al. (2022) · JCO Global Oncology · doi:10.1200/go.22.00119 · Cited by 18
Mateos, M., Chari, A., Usmani, S. Z., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.02.006 · Cited by 17
Self-citationMukhopadhyay, P., Abdullah, H. A., Opalinska, J., Paka, P., Richards, E., Weisel, K. C., Trudel, S., Mateos, M., Dimopoulos, M. A., & Lonial, S. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01212-0 · Cited by 21
Self-citationAlhuraiji, A., Naqvi, K., Huh, Y. O., Ho, C., Verstovšek, S., & Bose, P. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1264 · Cited by 17
The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
Salgado, L. R., Wang, S., Adler, A., Chang, S., Ru, M., Moshier, E. L., Dharmarajan, K. V., Cho, H. J., & Bakst, R. L. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.09.009 · Cited by 18
“Radiation dose group 20 Gy 171 (61%) 98 (57%) 73 (68%) 20-30 Gy 35 (13%) 25 (15%) 10 (9%) 30 Gy 73 (26%) 49 (28%) 24 (22%) Dose (Median, range) 20 (2-40) 20 (8-40) 20 (2-40) Radiation fractions (Median, range) 10 (1-20) 10 (1-20) 10 (1-20)”
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient
Ghobrial, I., Cruz, C. H., Garfall, A. L., Shah, N. D., Munshi, N. C., Kaufman, J. L., Boise, L., Morgan, G. J., Adalsteinsson, V. A., Manier, S., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.02.004 · Cited by 17
Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol
Hamadeh, I. S., Reese, E. S., Arnall, J. R., Kachur, E., Martin, A. L., Schneider, M., Friend, R. N., Paul, B. A., Atrash, S., Bhutani, M., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.02.014 · Cited by 16
Self-citationSato, S., Kamata, W., Okada, S., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-03005-6 · Cited by 17
Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice
Hamadeh, I. S., Moore, D. C., Martin, A. L., Karabinos, A., Hill, H., Ndiaye, A. P., Robinson, J., Paul, B. A., Atrash, S., Bhutani, M., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.02.014 · Cited by 17
Self-citationWang, J., Park, C., & Arroyo-Suárez, R. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1910687 · Cited by 18
“In May 2020, data access was granted to three randomized, open-label, multicenter, active-controlled trials available on the platform which studied clinical efficacies of daratumumab and its comparators, the POLLUX (NCT02076009) trial comparing daratumumab, lenalidomide, plus dexamethasone (DRd) with lenalidomide plus…”
MethodBlommestein, H. M., Franken, M. G., van Beurden-Tan, C. H. Y., Blijlevens, N. M. A., Huijgens, P. C., Sonneveld, P., Groot, C. A. U., & Zweegman, S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3497 · Cited by 18
Suzuki, K., Nishiwaki, K., & Yano, S. (2021) · Cancers · doi:10.3390/cancers13194867 · Cited by 16
Self-citationIdentification of patients at high risk of secondary extramedullary multiple myeloma development
Štork, M., Ševčı́ková, S., Minařík, J., Krhovská, P., Radocha, J., Pospíšilová, L., Brožová, L., Jarkovský, J., Špıčka, I., Štraub, J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17925 · Cited by 17
Current Treatment Approaches to Newly Diagnosed Multiple Myeloma
Ghandili, S., Weisel, K. C., Bokemeyer, C., & Leypoldt, L. B. (2021) · Oncology Research and Treatment · doi:10.1159/000520504 · Cited by 17
Arnall, J. R., Maples, K. T., Harvey, R. D., & Moore, D. C. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211058754 · Cited by 17
Lagreca, I., Riva, G., Nasillo, V., Barozzi, P., Castelli, I., Basso, S., Bettelli, F., Giusti, D., Cuoghi, A., Bresciani, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095242 · Cited by 18
Böckle, D., Tabares, P., Zhou, X., Schimanski, S., Steinhardt, M., Bittrich, M., Seebacher, E., Ulbrich, M., Wilnit, A., Metz, C., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18249 · Cited by 17
Martin, T. G., Mikhael, J. R., Hájek, R., Kım, K., Suzuki, K., Hulin, C., Garg, M. K., Quach, H., Sia, H., George, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006713 · Cited by 17
“In the POLLUX (Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone [DRd] vs Lenalidomide and Dexamethasone [Rd] in Subjects With Relapsed or Refractory Multiple Myeloma) study of patients with MM who had received at least 1 prior line of therapy, an MRD negativity rate of 22% was achieved in the darat…”
BackgroundResultSelf-citationMizuno, S., Kawamura, K., Hanamura, I., Sunami, K., Mori, T., Nakamura, F., Iida, S., Nakazawa, H., Makita, M., Kako, S., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0478-4 · Cited by 16
Harnessing immunotherapy for pediatric T-cell malignancies
Diorio, C. J., & Teachey, D. T. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1732819 · Cited by 17
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016
Terpos, E. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.010 · Cited by 16
“Regarding the Pollux trial (DaraRd vs Rd [21]), the updated analysis, after a median follow-up of 13.”
MethodSeefat, M. R., Cucchi, D. G. J., Dirven, S., Groen, K., Zweegman, S., & Blommestein, H. M. (2021) · Cancers · doi:10.3390/cancers13225606 · Cited by 18
“263 USD 1,156,868 USD 1,369,062 Minimally 1 prior LOT Median prior LOTs: 1 POLLUX trial [44] Zhang et al.”
BackgroundSaldarriaga, M. M., Darwiche, W., Jayabalan, D. S., Monge, J., Rosenbaum, C. A., Pearse, R. N., Niesvizky, R., & Bustoros, M. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020011 · Cited by 16
“DARA combination with IMiDs (lenalidomide) and PIs (bortezomib) improved anti-MM activity and led to significant improvements in clinical outcomes in RRMM patients (87, 88) or untreated myeloma (89, 90), and DARA combinations were approved by FDA for the treatment of MM patients with at least one prior line of therapy…”
BackgroundRaab, M. S., Zamagni, E., Manier, S., Rodríguez‐Otero, P., Schjesvold, F. H., & Broijl, A. (2023) · eJHaem · doi:10.1002/jha2.743 · Cited by 17
Novel investigational drugs active as single agents in multiple myeloma
D’Agostino, M., Salvini, M., Palumbo, A. P., Larocca, A., & Gay, F. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1324571 · Cited by 16
“[43] Dimopoulos MA, Oriol A, Nahi H, et al.”
Iida, S., Suzuki, K., Kusumoto, S., Ri, M., Tsukada, N., Abe, Y., Aoki, M., & Inagaki, M. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2281-6 · Cited by 16
“9 month) [10] in 16 mg/kg cohort, and several phase 1/2 and phase 3 combination studies [13, 14, 19].”
BackgroundMethodSelf-citationMultiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017
Terpos, E. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.02.015 · Cited by 16
Reprint of “Immunomodulatory effects of CD38-targeting antibodies”
van de Donk, N. W. C. J. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.02.002 · Cited by 16
Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
Swan, D., Lynch, K., Gurney, M. E., & O'Dwyer, M. E. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719854171 · Cited by 16
Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma
Bal, S., Weaver, A., Cornell, R. F., & Costa, L. J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16130 · Cited by 16
Metadata
- Authors
- Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., Plesner, T., Yoon, S.-S., Ben Yehuda, D., Richardson, P. G., Goldschmidt, H., Reece, D., Lisby, S., Khokhar, N. Z., O’Rourke, L., Chiu, C., Qin, X., Guckert, M., Ahmadi, T., & Moreau, P.
- Affiliations
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-10-06
- Volume
- 375
- Issue
- 14
- Pages
- 1319-1331
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2528329272
- Cited by
- 1,445
- References
- 32
- Citations by year
- 2026: 50 · 2025: 78 · 2024: 78 · 2023: 108 · 2022: 138 · 2021: 221 · 2020: 236 · 2019: 175 · 2018: 193 · 2017: 148 · 2016: 15
- FWCI
- 168.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Spectrum Pharmaceuticals
- Celgene
- Incyte
- Otsuka Pharmaceutical
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- daratumumab, lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, minimal residual disease, complete response, neutropenia, thrombocytopenia, adverse events, monoclonal antibody therapy, combination therapy, overall response rate, safety and tolerability
- MeSH terms
- Lenalidomide, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Disease-Free Survival, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
